DCM
PYXS icon

Driehaus Capital Management’s Pyxis Oncology PYXS Stock Holding History

Driehaus Capital Management’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-418,632
Closed -$929K – 466
2025
Q3 		$929K Buy
+418,632
New +$603K 0.01% 383

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Driehaus Capital Management's PYXS Position: Q4 2025 in Review

Driehaus Capital Management sold out of Pyxis Oncology (PYXS) in Q4 2025, closing a stake of 418,632 shares — an estimated $929K sold.

Driehaus Capital Management first reported a position in PYXS in Q3 2025 and held it in 1 quarter. The position peaked at $929K in Q3 2025. 79 funds tracked by Wall St. Rank hold PYXS as of Q4 2025.

  • Driehaus Capital Management reported no remaining Pyxis Oncology position as of Q4 2025 after selling out during the quarter.
  • Driehaus Capital Management sold 418,632 Pyxis Oncology shares in Q4 2025, an estimated $929K.
  • Driehaus Capital Management first reported a position in Pyxis Oncology in Q3 2025 and held it in 1 quarter.
  • Driehaus Capital Management's Pyxis Oncology position peaked at $929K in Q3 2025.
  • 79 funds tracked by Wall St. Rank held Pyxis Oncology as of Q4 2025.

Based on Driehaus Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.